Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$0.65
-$0.02(-3.42%)
At close: 4:00 PM EDT
$0.65
-$0.02(-3.42%)
Day’s Range― - ―
52-Week Range$0.56 - $4.99
Previous CloseN/A
Volume45.97K
Average Volume (3M)115.36K
Market Cap
$19.98M
Enterprise Value$7.59
Total Cash (Recent Filing)$17.11M
Total Debt (Recent Filing)$311.32K
Price to Earnings (P/E)―
Beta3.28
Next Earnings
Aug 07, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding35,143,723
10 Day Avg. Volume125,555
30 Day Avg. Volume115,358
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside1900.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt reduces structural refinancing and interest-rate pressure for a clinical-stage biotech. With minimal leverage, the company can prioritize R&D funding choices without large fixed interest obligations, improving financial flexibility over the next several quarters.
Focused Cannabinoid PipelineA focused therapeutic niche (cannabinoid modulation for metabolic disease) provides a clear R&D strategy and potential first-mover advantage in an evolving specialty field. If clinical progress continues, this focused pipeline supports durable differentiation and partnership interest from larger pharma.
Authorized Shares Expanded For FlexibilityTripling authorized shares gives the company enduring capital-raising flexibility to fund clinical programs or strategic deals without needing additional charter amendments. This structural option reduces procedural friction for future financings or collaborations over the medium term.
Bears Say
No Revenue And Heavy Cash BurnSustained, large operating losses and negative free cash flow create a persistent funding gap that will likely require external capital. This undermines runway, increases dilution risk, and limits ability to scale operations or invest strategically without repeated financings over the coming months.
Deteriorating Shareholders' EquityA rapidly shrinking equity base erodes balance-sheet resilience and the ability to absorb continued losses. This materially raises the probability of dilutive financing or asset sales and constrains strategic options if R&D setbacks occur, affecting medium-term financial stability.
Nasdaq Listing & Bid-price Compliance RiskActive listing deficiencies are a structural governance and access-to-capital risk. Potential delisting or continued capital-market restrictions can shrink investor interest, complicate future financings, impair liquidity, and pressure management to pursue dilutive remedies within a defined regulatory timeline.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.56 and its highest was $4.99 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $19.98M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on May 11, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.309 by -$0.011.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 35,143,723 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.309. Following the earnings report the stock price went down -7.614%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
SKYE Company Deck
SKYE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$13.00
▲(1900.00% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
57.51% Insiders
2.67% Mutual Funds
<0.01% Other Institutional Investors
37.69% Public Companies and
Individual Investors